SLC5A2 and chronic kidney disease: We changed the eGFR cut-off value after completion of this study and after publication of the DAPA-CKD and EMPEROR-Reduced trial results, which showed beneficial effects of SGLT2 inhibitor treatment on renal function [6, 8].